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Summary
BAX and BAK are essential regulators of proapoptotic signaling, and the disruption of apoptosis is linked to the development
of cancer. To investigate the role of BAX and BAK in tumorigenesis, primary baby mouse kidney epithelial cells (BMKs)
from wild-type, BAX-, BAK-, or BAK- and BAK-deficient mice were transformed by adenovirus E1A and dominant-negative
p53 (p53DD). In wild-type BMKs, the expression of E1A and inactivation of p53 was sufficient for transformation but not
tumorigenesis. In contrast, E1A- and p53DD-transformed BAX- and BAK-deficient BMKs formed highly invasive carcinomas.
Transformed BMKs deficient for either BAX or BAK were also tumorigenic, but only when heterozygous for the remaining
bax or bak allele, the expression of which was lost in most resulting tumors. Thus, BAX and BAK function to suppress
tumorigenesis, and their deficiency was selected for in vivo.
Introduction implement death signaling, many of which occur in mitochon-
dria, and the means by which they are deregulated in disease,
still remain to be determined.Altered regulation of programmed cell death or apoptosis has
long been linked to the development of cancer (Johnstone et The t(14;18) translocation that results in overexpression of
antiapoptotic BCL-2 is the hallmark of human B cell follicularal., 2002), and mitochondria have emerged as gatekeepers in
many apoptotic signaling pathways (Wang, 2001). Members of lymphoma, and induction of BCL-2 expression is a feature of
other human tumors and their progression (Gross et al., 1999;the BCL-2 family of proteins that regulate apoptotic signaling
through mitochondria are key regulators of apoptosis in mam- Johnstone et al., 2002). Indeed, overexpression of antiapoptotic
BCL-2 family member BCL-xL in a mouse tumorigenesis modelsmalian development, and their deregulation is associated with
disease, particularly cancer (Gross et al., 1999). There are three accelerates tumor formation (Naik et al., 1996; Pelengaris et al.,
2002). Mutations in proapoptotic BCL-2 family member BAX orclasses of BCL-2 family members: those that act predominantly
to inhibit apoptosis (e.g. BCL-2, BCL-xL, and adenoviral E1B BAK have also been observed in human cancers, particularly
colon tumors that display microsatellite instability (Kondo et al.,19K); those that act predominantly to promote apoptosis (e.g.
BAX and BAK); and the BH3-only Bcl-2 family members (e.g. 2000; Rampino et al., 1997). Furthermore, BAX deficiency in
some transgenic mouse tumor models accelerates tumorBID, PUMA, NOXA, BAD, and NBK/BIK), that contain the BH3
interaction domain that act as regulators of the anti- and proapo- growth (Eischen et al., 2002; Shibata et al., 1999; Yin et al.,
1997), yet in others, the presence of BAX has a stimulatoryptotic family members (Gross et al., 1999). Signal transduction
events modify the activity of BH3-only proteins that in turn effect on tumorigenesis (Knudson et al., 2001). Although far
from being entirely clear, these and other observations suggestinteract with pro- or antiapoptotic family members to either
antagonize or activate their function. Stimulation of apoptosis that apoptosis may be disabled in some cases during human
tumor development, and that it can occur by the gain of acan therefore be achieved by antagonizing a survival activity
or by activating a death activity. The biochemical events that survival activity or the loss of a death activity.
S I G N I F I C A N C E
The role of apoptosis in tumorigenesis has largely been ascribed to an obligatory step for rapidly dividing epithelial cells to overcome
p53-mediated cell death triggered by the deregulation of the cell cycle or DNA damage. While loss of p53 function is often essential
for oncogenesis, the function of other death-promoting genes, such as bax and bak, in tumorigenesis and their functional interaction
with the p53 pathway has been less clear. Here we propose that a p53-independent apoptotic pathway that is regulated by BAX
and BAK is involved in tumor suppression. Understanding the mechanism and the molecular events regulating this pathway may
reveal novel targets for effective combinatorial therapeutic approaches to cancer treatment.
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Loss of function of the retinoblastoma (RB) tumor suppres- BAK act at the biochemical level in mitochondria once activated
by BH3-only proteins is the subject of much speculation, but itsor protein is associated with deregulation of cell growth control
and activation of p53-dependent apoptosis, suggesting that is linked to the release of proapoptotic signaling proteins from
the mitochondrial intermembrane space into the cytoplasmapoptosis may be a cellular response to the elimination of abnor-
mal, emerging tumor progenitors (White, 1994). The p53 tumor (Green and Evan, 2002).
Mouse embryo fibroblasts (MEFs), transformed MEFssuppressor, which is frequently mutated in human tumors (Hai-
naut and Hollstein, 2000), functions to activate apoptosis (Balint (Cheng et al., 2001; Wei et al., 2001; Zong et al., 2001), or
transformed baby mouse kidney epithelial cell lines (BMKs) (De-and Vousden, 2001). p53 regulates the transcription of genes
that promote cell growth arrest (El-Deiry et al., 1993), but also genhardt et al., 2002) derived from BAX- and/or BAK-deficient
mice have been useful in determining their role in apoptosis.activates expression of proapoptotic BH3-only Bcl-2 family
members (Nakano and Vousden, 2001; Oda et al., 2000; Yu et Similar to wild-type cells, cells deficient for either BAX or BAK
still release mitochondrial proteins and undergo apoptosis inal., 2001) that act as upstream regulators of proapoptotic BAX
and BAK in mitochondria (Cheng et al., 2001; Zong et al., 2001). response to cytotoxic agents and death receptor signaling,
whereas those deficient for both BAX and BAK are profoundlyDespite these indications that cancers emerge in part by de-
feating the capacity of cells to undergo apoptosis, clear relation- defective (Degenhardt et al., 2002; Wei et al., 2001). Thus, BAX
or BAK function in a redundant capacity to facilitate the releaseships between BCL-2 family members and cancer progression,
prognosis, and significance to treatment have often been ob- of mitochondiral proteins such as cytochrome c and SMAC/
DIABLO from the intermembrane space (Degenhardt et al.,scure. Nonetheless, understanding the function of BCL-2 family
members in mitochondria resides at the core of many apoptotic 2002; Wei et al., 2001). BAX- and BAK-deficient cells are also
resistant to death signaling by overexpression of BH3-only pro-signaling events.
Antiapoptotic BCL-2 family members appear to function at teins, indicating that they are required downsteam components
of these signaling pathways (Cheng et al., 2001; Zong et al.,least in part by interacting with and antagonizing proapoptotic
family members, either BAX and BAK or their upstream activa- 2001).
Binding to and inhibition of upstream BH3-only proteins,tors, the BH3-only proteins (Gross et al., 1999). Determining the
role and means by which BAX and BAK function is thus an or BAX and BAK themselves, by antiapoptotic BCL-2 family
members appears to be a means by which apoptosis is inhibited.essential component in understanding apoptotic signaling.
BAX-deficient mice display lymphoid hyperplasia, perturbation Expression of antiapoptotic Bcl-2 family members prevents
both BAX and BAK oligomerization and the release of proapo-of the regulation of ovarian cell death, and male germ cell hypo-
plasia (Knudson et al., 1995; Shindler et al., 1997). BAK-deficient ptotic proteins from mitochondria (Antonsson et al., 2000; De-
genhardt et al., 2002; Desagher et al., 1999; Jurgensmeier etmice are developmentally normal, whereas BAX- and BAK-
deficient mice have numerous developmental defects associ- al., 1998; Korsmeyer et al., 2000; Perez and White, 2000; Sun-
dararajan et al., 2001; Wei et al., 2001; Wei et al., 2000). Onceated with failure to undergo apoptosis, including accumulation
of excess cells within the central nervous and hematopoietic released, cytochrome c serves as an activator of caspase-9 in
the apoptosome, whereas SMAC/DIABLO represses an inhibitorsystems, and persistence of interdigital webs (Lindsten et al.,
2000). Thus, BAX and BAK are functionally redundant activators of caspase-9 activation, the inhibitor of apoptosis proteins (IAPs)
(Wang, 2001). Caspase-9 in turn activates caspase-3 and theof apoptosis; however, since most of the BAX- and BAK-defi-
cient animals die perinatally, investigation of whether they are cleavage of apoptotic substrates that mediate the dismantling of
the cell, morphologically recognized as cell death by apoptosisprone to tumor formation has been limited. Furthermore, BAX-
deficient mice display male sterility (Knudson et al., 1995), mak- (Cryns and Yuan, 1998).
While the role of this BAX and BAK mitochondrial deathing it difficult to evaluate BAK and BAX deficiency in tumor-
prone murine models. signaling pathway is essential in mediating cell death by toxic
stimuli and by death receptor signaling, and in development,Antiapoptotic BCL-2 family members such as BCL-2,
BCL-xL, or E1B 19K suppress apoptosis by regulating the func- their role in oncogenic transformation and tumorigenesis remained
to be addressed. Transformation of primary BMK or baby rattion, either directly or indirectly, of proapoptotic family members
BAX and BAK. BAX and BAK function in mitochondria is acti- kidney (BRK) epithelial cells requires expression of adenovirus
E1A to drive cell proliferation, and inactivation of p53 with avated by interaction with BH3-only proteins via binding of their
BH3 to BAX and/or BAK. BH3-only proteins act through activa- dominant-negative p53 mutant or p53 diciency, to relieve p53-
dependent inhibition of cell growth and induction of apoptosistion of BAX and BAK to signal changes in mitochondria that
propagate death signaling. Interaction of a BH3-only protein (Debbas and White, 1993; Degenhardt et al., 2002). Suppression
of the transforming activity of E1A is exquisitely p53-dependent,tBID with BAX or BAK, for example, causes BAX and BAK to
undergo changes in protein conformation followed by homo- as E1A will efficiently transform primary BMK cells derived from
p53-deficient mice, but not those from wild-type mice (Degen-or heteroligomerzation into high molecular weight protein com-
plexes (Desagher et al., 1999; Eskes et al., 2000; Kluck et al., hardt et al., 2002). E1A alone does not transform primary BMK
cells from BAX- and BAK-deficient mice, indicating that BAX1999; Korsmeyer et al., 2000; Perez and White, 2000; Sundara-
rajan et al., 2001; Sundararajan and White, 2001; Wei et al., and BAK are dispensable for p53-dependent suppression of
transformation (Degenhardt et al., 2002). Since a gain-of-func-2000). BCL-2 and BCL-xL appear to bind and inhibit BID or
tBID to prevent tBID from interacting with and inducing the tion of antiapoptotic BCL-2 family members and loss-of-func-
tion mutations in proapoptotic BAX have been reported in hu-oligomerization of BAX and BAK (Cheng et al., 2001), whereas
E1B 19K binds directly to both BAX and BAK and prevents their man tumors (Johnstone et al., 2002), we tested the requirement
for BAX and BAK in tumorigenesis. E1A plus dominant-negativeoligomerization (Perez and White, 2000; Sundararajan et al.,
2001; Sundararajan and White, 2001). Exactly how BAX and mutant p53 (p53DD) transformed wild-type BMK cell lines were
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Table 1. Incidence of tumor formation by transformed wild-type or BAX- and BAK-deficient BMK cell lines in nude mice
Genotype Tumors/sites of injection
Cell line bax bak p53 105 cells/injection 106 cells/injection** 107 cells/injection**
W1 / / /* 0/5 0/5 0/4
W3 / / /* 0/5 0/5 0/5
D1 / / /* 1/5 5/5 4/5
D3 / / /* 1/5 5/5 5/5
W4 / / / 0/5
W5 / / / 0/5
p53/-1 / / / 0/5
p53/-2 / / / 0/5
* p53 is inactivated by p53DD expression (Figures 4 and 5; Degenhardt et al., 2002).
** P value is less than 0.05.
not tumorigenic when injected into nude mice, nor were p53- mained intact in all of the W, X, and K BMK cell lines (Degenhardt
et al., 2002). D1, D2, and D3 cells are also resistant to apoptosisdeficient BMK cell lines transformed by E1A alone. In contrast,
induction by infection with proapoptotic adenoviruses (CuconatiE1A plus p53DD transformed BAX- and BAK-deficient BMK
et al., 2002), and numerous other death stimuli, including over-cell lines were profoundly tumorigenic, forming highly invasive
expression of BH3-only proteins (K.D., E.W., D. Nelson, and R.carcinomas. Moreover, transformed BMK cell lines that were
Sundararajan, unpublished data). The inability of BAX and BAKBAX-deficient and heterozygous for BAK formed tumors that
deficiency to ameliorate p53-dependent suppression of trans-lost BAK expression. Similarly, BAK deficiency and BAX hetero-
formation and facilitate oncogenic transformation by E1Azygosity permitted growth of tumors that had lost BAX expres-
prompted us to examine their role in tumorigenesis. To test ifsion with high frequency. Thus, BAX and BAK suppressed tumor
deficiency in BAX, BAK, or BAX and BAK affected the ability offormation, and their loss of function was selected for in vivo
transformed BMKs to form tumors in vivo, each cell line wasduring tumor development. The role of BAX and BAK in sup-
injected into nude mice and assessed for tumor xenograft for-pressing tumor formation was p53-independent; therefore, devel-
mation and growth. W1 and W3 and D1 and D3 cells wereoping the means to overcome the loss of BAX and BAK function
injected subcutaneously into nude mice at concentrations ofin tumors may yield a novel approach to cancer treatment.
105, 106, or 107 cells per injection site. Injected cells initially
formed a small subcutaneous mass that began to dissipate oneResults
week postinjection of W1 and W3 cells (Figure 1). No evidence
of injected transformed cells was apparent beyond two to threeDeficiency in both BAX and BAK promotes
tumorigenesis in mouse xenografts weeks postinjection through to the termination of the experiment
at either 45 days (W3) or 58 days (W1) (Figure 1). The D1 or D3Stable BMK cell lines transformed with E1A plus p53DD were
derived from primary kidney epithelia from wild-type (W), bax/ cells also formed a subcutaneous mass upon injection; however,
in contrast to the W1 and W3 cells, the size of the mass steadily(X), bak/ (K), and bax/ bak/ (D) mice (Table 1; Degenhardt
et al., 2002). Transformation of wild-type, BAX-, BAK-, or BAX- increased throughout the duration of the experiment to the point
at which and animals were euthanized (D3 with W3 on day 45,and BAK-deficient primary BMK cells required both expression
of E1A and inactivation of p53 to select for functional transfor- and D1 with W1 on day 58). Tumor formation occurred with
high efficiency at 107 or 106 injected D1 and D3 cells, and wasmation. Three independently cloned cell lines from each geno-
type were analyzed (W1, W2, W3, X1, X2, X3, K1, K2, K3, D1, less frequent with 105 cells (Table 1). W1 and W3 cells did not
form tumors in any of the injected mice at any injected cellD2, D3). All BMK cell lines expressed similar levels of E1A and
p53DD, whereas X1, X2, and X3, and D1, D2, and D3 were number (Table 1).
The failure of transformed W1 and W2 BMKs to form tumorsdeficient for BAX expression, and K1, K2, and K3, and D1, D2,
and D3 were deficient for BAK expression. Wild-type and BAK- was not due to incomplete inactivation of p53 by the p53DD
mutant, since E1A-alone transformed BMK cell lines deriveddeficient BMK cell lines were derived from mice heterozygous
for BAX (bax/), and two BAX-deficient BMK cell lines (X2 and from p53-deficient mice were also not tumorigenic, nor were the
E1A plus p53DD transformed wild-type BMK cell lines derived inX3) were derived from mice heterozygous for BAK (bak/),
whereas X1 was homozygous wild-type for BAK (bak/) (Table parallel (Table 1). The expression of E1A, which inactivates RB,
coupled with inactivation of p53, is an extremely efficient func-1; Degenhardt et al., 2002). Cell lines of each genotype were
derived from multiple animals, except for those deficient for tional combination for transforming primary rodent epithelial
cells in vitro (Debbas and White, 1993). The transforming activityboth BAX and BAK that were independently derived E1A plus
p53DD transformed clones from a single animal, since the peri- resulting from E1A expression and p53 inactivation is not notice-
ably influenced by mouse genetic background, or even rodentnatal survival of these animals was rare (Degenhardt et al., 2002;
Lindsten et al., 2000). D1, D2, and D3 cells were resistant to species, indicating that both activities are fundamentally re-
quired for the transformation of epithelial cells. These activities,death signaling by TNF- in short-term and long-term clono-
genic survival assays, due to the inability to release cytochrome however, were apparently not sufficient to confer the ability of
W BMK cell lines derived from a classic rodent transformationc and activate caspase-9, whereas the apoptotic pathway re-
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Figure 1. Tumor formation of wild-type and BAX- and BAX-deficient BMK cell
lines in nude mice
107 cells from wild-type (W1 and W3) and BAX- and BAK-deficient (D1 and
D3) transformed BMK cell lines were injected subcutaneously into nude nice
and evaluated for tumor growth with time. Figure 2. Morphology of tumors formed by BAX- and BAK-deficient BMK cell
A: Representative animals injected with W1 (left) or D1 (right) photographed lines
at 60 days postinjection. The D1-injected animal displays a typical tumor A: Excised D1 tumor 1 cm in diameter at time of euthanasia, from the
mass that is absent from the W1 injected animal. experiment described in Figure 1 and Table 1, with apparent vascularization.
B: Quantitation of tumor volume over time. The volume of the tumor mass B: Representative H&E staining of a thin section from a D1 tumor displaying
arising from W1-, W3-, D1-, and D3-injected mice was determined at the tumor tissue (T), tumor giant cells (TGC), and invasion of skeletal muscle
indicated intervals. The average tumor volume for 4/5 D1- and 5/5 D3- (SKM).
injected, tumor-bearing animals was determined. Quantitation of the inci- C: Representative H&E staining of a thin section from another D1 tumor (T)
dence of tumor formation by W1, W3, D1, and D3, for all animals at three that arose in a different mouse displaying invasion of dermis (DRM). All
different injected cell numbers, is presented in Table 1. tumors from D1- and D3-injected mice from Table 1 were evaluated similarly
and classified as highly invasive carcinomas.
assay to establish tumors in nude mouse xenografts. In contrast,
E1A plus p53DD transformed BMK cell lines derived from BAX- All tumors arising from injected D1 and D3 cells (107 cells in-
and BAK-deficient mice formed vigorous tumors with high fre- jected) were excised at time of euthanasia and subjected to
quency with a 10-fold lower amount of injected cells. sectioning and hematoxylin-eosin (H&E) staining to examine
tumor pathology. All nine tumors were highly similar undifferenti-
BAX- and BAK-deficient transformed BMKs ated carcinomas displaying sheets of clustered adherent cells
with large pleiomorphic nuclei and scanty cytoplasm (Figuresform highly invasive carcinomas
Necropsy revealed large (1 cm) highly vascularized tumors at 2B and 2C). Tumor cells had a high mitotic rate, and tumor
giant cells were present. Blood vessels were also apparentthe site of injection of D1 and D3 cells (Figure 2A), and no
evidence of tumors was apparent in W1 and W3 injected mice. throughout the tumors (data not shown). Tumor tissue was found
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Table 2. BAX and BAK genotype and incidence of tumor formation in nude mice
Genotype Tumors/sites of injection
Cell line bax bak Exp. 2* Exp. 3*
bax/bak/  bax/bak/ W1 / / 0/5
bax/bak/  bax/bak/ W2 / / 0/5 0/5
bax/bak/  bax/bak/ W3 / / 0/5
bax/bak/  bax/bak/ X1 / / 0/5 0/5
bax/bak/  bax/bak/ X2 / / 5/5 5/5
bax/bak/  bax/bak/ X3 / / 5/5 5/5
bax/bak/  bax/bak/ and bax/bak/  bax/bak/ K1 / / 5/5 5/5
bax/bak/  bax/bak/ and bax/bak/  bax/bak/ K2 / / 5/5 5/5
bax/bak/  bax/bak/ and bax/bak/  bax/bak/ K3 / / 5/5 5/5
bax/bak/  bax/bak/ and bax/bak/  bax/bak/ D1 / / 5/5 5/5
bax/bak/  bax/bak/ and bax/bak/  bax/bak/ D2 / / 4/5 4/5
bax/bak/  bax/bak/ and bax/bak/  bax/bak/ D3 / / 5/5
* P value is less than 0.05
invading skeletal muscle (Figure 2B), dermis (Figure 2C), fat, (Figure 3). Interestingly, tumorigenic X2 and X3, while BAX-
deficient, are heterozygous for BAK (bak/), whereas nontu-and mammary fat pad, and some tumors displayed evidence
of necrosis in the center (data not shown). morigenic X1 is homozygous wild-type for BAK (bak/). Fur-
thermore, all three tumorigenic BAK-deficient BMK cell lines
were heterozygous for BAX (bax/). These observations pro-BAK heterozygosity facilitates tumorigenesis
in the absence of BAX moted us to examine BAX and BAK expression in tumors derived
from BAX or BAK singly deficient cell lines to test for loss ofThe formation of tumors by the BAX- and BAK-deficient, but
not wild-type, BMK cell lines led us to investigate the individual expression of the only remaining BAX or BAK allele.
contribution of BAX and BAK to tumor formation. W1, W2, and
W3, and BAX- and BAK-deficient transformed BMK cell lines Tumor formation in vivo selects
for BAX and BAK deficiencyD1, D2, and D3, were injected into nude mice alongside singly
BAX- (X1, X2, and X3) or BAK- (K1, K2, and K3) deficient trans- X2, X3, K1, K2, and K3, along with W (BAX- and BAK-expressing)
and D (BAX- and BAK-deficient) controls, were evaluated forformed BMK cell lines in two independent experiments. All three
wild-type BMK cell lines failed to form tumors in any of the 20 BAX and BAK expression at the time of injection, in the resulting
tumor, and in tumor derived cell lines (TDCLs) within three pas-injected mice by seven weeks postinjection, whereas all three
BAX- and BAK-deficient BMK cell lines formed tumors in 23 sages of recovery from the tumor. X2 and X3 expressed BAK
but not BAX at the time of injection into nude mice as expectedout of 25 mice (Table 2). Although there were minor differences
(less than 2-fold) in growth rates for the W, X, K, and D cell (Figure 4A). Similarly, K1, K2, and K3 expressed BAX but not
BAK at the time of injection (Figure 4A). When the resultinglines, there was no correlation with tumorigenesis (data not
shown). Interestingly, two of the three BAX singly deficient BMK tumors were evaluated for BAX and BAK expression, only traces
of (X3, K1, K3) or no (X2, K2) BAX and BAK expression werecell lines (X2 and X3) formed tumors, whereas one (X1) did not
(Table 2, Figure 3). All three BAK singly deficient BMKs (K1, K2, found. The amount of BAK in the X3 tumor sample was similar
to the amount found in K1 and K3 tumor samples (Figure 4A).and K3) formed tumors (Table 2), but with delayed kinetics
Figure 3. Tumor formation of wild-type, BAX-,
BAK-, and BAX- plus BAK-deficient BMK cell lines
in nude mice
107 cells from W1, W2, and W3, BAX-deficient (X1,
X2, and X3), BAK-deficient (K1, K2, and K3), and
BAX- and BAK-deficient (D1, D2, and D3) trans-
formed BMK cell lines were injected subcutane-
ously into nude nice, and tumor volume was
quantitated over time. The volume of the tumor
mass arising from injected mice was determined
at the indicated intervals. The average tumor
volume for animals injected with each of the
12 transformed BMK cell lines was determined.
Quantitation of the incidence of tumor formation
by all 12 BMK cell lines for all animals in two inde-
pendent experiments is presented in Table 2.
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Figure 4. Tumor formation in vivo selects for loss
of BAX and BAK expression in heterozygotes
A: Western blot for BAX and BAK expression in
the W2 control BMK cell line, X2, X3, K1, K2, and
K3 cell lines (CL) at time of injection, resulting
tumor tissue (Tumor), and tumor derived cell line
(TDCL) within three passages of recovery from
tumor. BAX-deficient transformed BMKs X2 and
X3 express only BAK at time of injection into nude
mice, whereas tumors and tumor-derived cell
lines resulting from X2 and X3 injection have re-
duced or nil BAK expression. Similarly, BAK-defi-
cient K1, K2, and K3 express only BAX at time of
injection into nude mice, whereas tumors and
tumor derived cell lines resulting from K1, K2, and
K3 injection have reduced or nil BAX expression.
The BAX- and BAK-deficient D3 BMK cell line, re-
sulting tumor, and tumor-derived cell line repre-
sent a negative control for BAX and BAK expres-
sion. The scant BAX and BAK expression
appearing in tumor tissue likely results from contri-
bution of normal mouse tissue vasculature to the
tumor. Samples from all cell lines, tumors, and
tumor-derived cell lines express E1A and p53DD
by Western blotting, as expected. The actin
Western blot serves as a reference for equating
protein loading among different samples.
B: Quantitation of loss of BAX and BAK protein
expression in TDCLs for all 8 transformed BMK cell
lines that formed tumors, in two independent ex-
periments.
K1 and K3 cell lines had no BAK when injected into the nude that their genotype is stable. Selective pressure, such as that
provided in a mouse xenograft, may be required for loss of BAXmice; thus, any BAK in the resulting tumor sample was contrib-
uted by the host, which likely resulted from incorporation of and BAK expression. All BMK cell lines, and the corresponding
resulting tumors and tumor derived cell lines, expressed E1Anormal murine vasculature into tumor. This direct analysis of
BAX and BAK expression in tumor tissue suggests that BAX or and p53DD as expected (Figure 4A).
BAK was lost during the process of tumorigenesis of the X and
K BMK cell lines retaining only a single allele of BAX or BAK. Loss of BAX and BAK expression in tumors results
from loss of heterozygosityTumor tissue was isolated and physically dispersed, and
placed in culture in vitro, from one of each of four tumors that Tumor formation of transformed BMKs deficient for BAX that
were heterozygous for BAK and vice versa suggested that aresulted from injection with the X2, X3, K1, K2, and K3 cell lines.
Isolated tumor cells survived and grew with high efficiency in loss of heterozygosity of the remaining bax or bak allele and
the loss of both BAX and BAK expression in tumors was in-culture with no apparent affect on growth or viability, and the
resulting TDCLs were examined for BAX and BAK expression volved. Loss of heterozygosity through heterologous recombi-
nation would result in both alleles with same gene disruption;within three passages of isolation from tumor. As is the case
with the tumors themselves, nearly all X and K TDCLs lacked therefore, the same polymerase chain reaction (PCR) genotyp-
ing strategy that was used to identify the targeted disruption inexpression of both BAX and BAK, even though one or the other
was expressed at the time of injection (Figure 4A). This loss of mice was used to identify the loss of heterozygosity in the
TDCLs. TDCLs rather than tumor tissue were used becauseBAX expression occurred in 27 of 29 TDCLs that resulted from
injection of K1, K2, and K3 (Figure 4B). Loss of BAK expression PCR genotyping is extremely sensitive, and tumor tissue was
partially composed of vasculature contributed by the wild-typeoccurred in 20 of 20 TDCLs that resulted from injection of X2
and X3 (Figure 4B). Since the loss of BAX and BAK expression xenograph host. TDCLs that arose from transformed BMKs de-
ficient in BAX (X2 and X3) showed a loss of the remaining bakin the isolated tumors was sustained in culture, it was not the
result of suppression of expression within the tumor. Further- allele, indicated by the loss of the wild-type PCR product in 8
of 8 cases, whereas the parental cell lines were heterozygousmore, loss of BAX or BAK expression in W, X, or K BMK cell
lines has never been observed in vitro in culture, indicating for bak and expressed BAK at the time of injection into nude
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Figure 5. Tumor formation in vivo selects for loss of BAX and BAK expression by loss of heterozygosity and apoptosis resistance in vitro
A: PCR genotyping for wild-type (WT) and knockout (KO) alleles of bax and bak in W2 control, BAX- and BAK-deficient D3 control, X2, X3, K1, K2, and K3
cell lines (CL) at time of injection, and in the resulting tumor derived cell lines (TDCL) within three passages of isolation from four independent tumors derived
from each of the indicated cell lines. Western blot for BAX, BAK, and p53DD expression in parallel with genotyped samples. The actin Western blot serves
as a reference for equating protein loading among different samples.
B: Parental CL and TDCL viability following treatment with stuarosporine (4 M) for 24 hr. Viability was assessed by trypan blue exclusion for BAX- and BAK-
deficient D3 control, parental CL (X1, X2, K1, K2, K3) and their tumor-derived counterparts (TDCL).
mice (Figure 5A). Genotyping of the TDCLs that arose from that loss of BAK during tumor formation resulted from a loss of
heterozygosity in all cases, and that the loss of BAX expressionBMKs deficient in BAK showed a loss of the remaining bax
allele in 8 of 10 TDCLs that lost BAX protein expression, whereas predominately resulted from loss of heterozygosity.
the parental cell lines (K1, K2, and K3) were heterozygous for
bax and expressed BAX at the time of injection into nude mice Tumor-derived cell lines gain apoptosis
resistance in vitro(Figure 5A). The apparent retention of the wild-type bax allele
in a few TDCLs could be due to low-level contamination with To examine the apoptotic potential of the BMK cell lines and their
tumor-derived counterparts, we characterized their apoptoticwild-type tissue from the host. Alternatively, the loss of BAX
protein expression in K1 TDCL1 and 3 (Figure 5A) could result response to in vitro treatment with staurosporine. We have pre-
viously reported that BAX or BAK expression in transformedfrom a mutation in bax or epigenetic effects on BAX expression.
Retention of BAX protein expression in K1 TDCL4 and K2 TDCL1 BMK cell lines is sufficient for induction of apoptosis in vitro,
whereas deficiency in both BAX and BAK confers resistance tomay result from functional inactivation of BAX, either directly or
indirectly. All BMK cell lines and their tumor-derived counter- TNF- and a wide variety of other apoptotic stimuli (Degenhardt
et al., 2002). The parental CLs or TDCLs were untreated orparts expressed p53DD (Figure 5A). These results demonstrated
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treated with staurosporine for 24 hr and analyzed for viability Perhaps inhibition of cell proliferation and induction of apoptosis
by p53 represent redundant functions capable of inhibiting on-by trypan blue exclusion (Figure 5B). When treated with stauro-
sporine, the viability of the BAX- or BAK-containing BMK cell cogenic transformation. By possessing at least two mechanisms
for suppressing transformation, p53 may act efficiently at alines (X13, X14, K1, K2, K3) decreased dramatically (Figure 5B).
In contrast, all of the TDCLs were highly resistant to stauro- critical step to prevent the emergence of oncogenically trans-
formed cancer cells.sporine-mediated apoptosis and were indistinguishable from
the BAX- and BAK-deficient D3 BMK cell line (Figure 5B). K1 Evidence that p53 may be capable of inducing apoptosis
in the absence of BAX and BAK is more difficult to come by.TDCL-4 and K2 TDCL-1, which retained BAX expression, were
also resistant to staurosporine-induced apoptosis in vitro (Figure Transformed foci initiated by E1A in both wild-type and BAX-
and BAK-deficient BMK cells do regress, consistent with induc-5B). These results are consistent with selection during tumori-
genesis for apoptotic resistance by the loss of both BAX and tion of p53-dependent and BAX- and BAK-independent cell
death (Degenhardt et al., 2002). BAX and BAK deficiency doesBAK expression and function.
confer resistance in the short-term to DNA damage-induced
cell death (Wei et al., 2001), which p53 participates in, althoughDiscussion
it is not known if this failure to undergo apoptosis is sustained
in the long-term (Wei et al., 2001). If a BAX- and BAK-indepen-There is significant evidence that p53 acts as an upstream regu-
lator of proapoptotic BAX and BAK. The gene encoding BAX is dent or a mitochondria-independent apoptotic pathway exists
for p53-mediated cell death, as it does for death receptor signal-a transcriptional target of p53 in humans (Miyashita and Reed,
1995), although this activity is not conserved in the mouse ing in some cell types (Scaffidi et al., 1999), this will be of great
interest to identify.(Schmidt et al., 1999). BAK has also been reported to be upregu-
lated by p53 (Pearson et al., 2000; Pohl et al., 1999). Genes There is substantial evidence that apoptosis plays a role in
the development of human cancer, and that it may be a majorencoding the BH3-only proteins PUMA and NOXA are directly
transcriptionally transactivated by p53 (Nakano and Vousden, mechanism of action of current anticancer drugs (Johnstone et
al., 2002; Zhang et al., 2000). It is, however, not always entirely2001; Oda et al., 2000; Yu et al., 2001), and PUMA or NOXA
overexpression induces apoptosis in wild-type but not BAX- clear where or when apoptosis comes into play. This may merely
be a consequence of the complex and variable nature of cancerand BAK-deficient MEFs and BMKs (Cheng et al., 2001; Zong
et al., 2001; D. Nelson, K.D., and E.W., unpublished data). Thus, emergence in different tissues and circumstances. These events
are compounded by the multitude of mutational events, in ap53 has the capacity to activate the transcription of upstream
activators of BAX and BAK proapoptotic function, and possibly myriad of combinations varying over time and treatment, that
are observed in human cancers. In the BMK epithelial cell model,BAX and BAK themselves. In response to induction of wild-type
p53, BAX and BAK undergo conformational changes indicative we have established that transformation and tumorigenesis are
distinct and separable functions. While inactivation of the RBof activation, coordinate with the release of cytochrome c and
SMAC/DIABLO from mitochondria, and undergo caspase-9 pathway by E1A expression and inhibition of p53 function ap-
pear critical for the establishment of immortal, transformed epi-and -3 activation (Henry et al., 2002). Nonetheless, BAX and BAK
appear to be dispensable for p53 to suppress transformation thelial cells in vitro, these cells apparently lack the ability to
survive and grow efficiently in vivo in nude mouse xenografts.(Degenhardt et al., 2002), and BAX- and BAK-deficient mice
are not overtly tumor-prone (Lindsten et al., 2000) as are p53- Inactivation of both BAX and BAK was required for tumor
growth, and was selected for in vivo during tumorigenesis.deficient mice (Donehower et al., 1992). Two mutually inclusive
possibilities to explain these results are that p53 can suppress Transformed cells deficient for BAX, that also possess heterozy-
gous deficiency in bak, underwent selection for tumors in vivotransformation by a nonapoptotic mechanism (El-Deiry et al.,
1993), or that p53 has the ability to induce cell death by a that had lost expression of the remaining bak allele. The con-
verse was true for transformed cells that are deficient in BAKBAX- and BAK-independent mechanism. However, once p53
inactivation has occurred, abrogation of BAX- and BAK-medi- and heterozygous for bax. In most cases, the loss of BAX and
BAK expression resulted from loss of heterozygosity. In theated apoptosis may be a rate-limiting step for tumorigenesis.
In support of a nonapoptotic mechanism of p53-dependent occasional tumors that maintain expression of BAX, it is not
clear if bax is mutated or if there are mutations elsewhere insuppression of transformation, inhibitors of apoptosis such and
BCL-2 or adenovirus E1B 19K facilitate transformation of pri- the apoptotic pathway that could block BAX function. BAX and
BAK deficiency derived in vivo during tumorigenesis, and in themary BRK cells by E1A substantially less efficiently than direct
inactivation of p53 (Rao et al., 1992; White et al., 1992). BRK cell rare cases of TDCLs where BAX expression was maintained in
tumorigenesis, conferred apoptosis resistance in vitro. Thus,lines transformed by E1A and a temperature-sensitive mutant
of p53 undergo apoptosis when p53 reverts to the wild-type tumorigenesis in vivo selects for apoptotic resistance that in
most cases can be attributed to the loss of BAX and BAK.conformation (Debbas and White, 1993), and if this p53-depen-
dent apoptosis is rescued by BCL-2 or E1B 19K expression, the Similar to the molecular events that contribute to human
tumorigenesis, E1A expression and p53 inactivation are bothcells undergo complete and sustained cell cycle arrest (Chiou et
al., 1994; Sabbatini et al., 1995a). This p53-mediated cell cycle associated with induction of genetic instability that may facilitate
the selection process for loss of both BAX and BAK expression.arrest is coincident with the transactivation of p21WAF1 (Han et
al., 1996; Sabbatini et al., 1995b) and is reversible upon restora- The redundant function of BAX and BAK in promoting apoptosis
may, however, reduce the likelihood that apoptotic functiontion of p53 to the mutant conformation (Chiou et al., 1994;
Sabbatini et al., 1995a). Thus, ameliorating p53-dependent apo- would be abrogated as a means to promote tumorigenesis.
Nonetheless, mutations in, or reduced expression of, BAX orptosis has no affect on induction of growth arrest by p53, and
even allows the cell cycle arrest function of p53 to be revealed. BAK have been observed in human tumors (Johnstone et al.,
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below). Tumor growth from each cell line was monitored by measurements2002; Kondo et al., 2000; Rampino et al., 1997), BAX mutations
with a 6-inch dial caliper (General Tools Mfg. Co., New York, NY) weekly.confer a growth advantage during clonal tumor evolution (Ionov
Tumor growth rates were calculated as described previously (Streit et al.,et al., 2000), and inhibition of apoptosis in murine models pro-
1999). Tumor-bearing mice and controls were sacrificed and the tumors were
motes late-stage tumorigenesis (Eischen et al., 2002; Naik et excised under sterile conditions. Tumors were sectioned and processed for
al., 1996; Pelengaris et al., 2002: Shibata et al., 1999; Yin et al., histology, protein analysis, DNA preparation, and isolation of tumor derived
1997). Furthermore, deficiency in both BAX and BAK confers cell lines. A 2 mm section of the tumor was fixed in Omnifix 2000 according
to the manufacturer’s instructions (FR Chemical Co., Mt. Vernon, NY) andresistance to apoptosis mediated by death receptors (Degen-
sent to the Mutant Mouse HistoPathology Laboratory (U.C. Davis, Davis,hardt et al., 2002; Wei et al., 2001), and treatment of sensitive
CA) for H&E staining and pathology. Approximately one-fifth of the tumortumor cells with death receptor ligands also selects for BAX
was placed in tissue culture media, mechanically disrupted by pipeting, and
mutations (LeBlanc et al., 2002). Thus, the process of tumorigen- recultured for three passages into tumor derived cell lines. Approximately
esis may subject genetically unstable tumor cells to selective one-fifth of the tumor was frozen in liquid nitrogen and processed into
pressure to disable apoptosis through loss-of-function in BAX Western blot extracts (Geoerger et al., 2002) by homogenizing the tumor in
ice cold lysis buffer (150 mM NaCl,1 mM MgCl2, 1 mM KH2PO4, 1 mM EDTAand/or BAK that may confound treatment strategies.
[pH 6.4], 1 mM dithiotretiol, 1 mM phenylmethylsulfonyl fluoride, 20 g/mlThe mechanism by which BAX and BAK suppress tumor
leupeptin, 10 g/ml aprotinin, and 10 g/ml pepstatin A) using an Ultraformation is not known, but may be related to the necessity of
Turrax T8 tissue homogenizer (IKA-Werke GMBH & Co., Staufen, Germany).
cells from highly invasive carcinomas to survive at foreign or The x2 test and Fisher test for exactness to were used to calculate P values
distant locations. Growth factor limitations may restrict survival on pooled results of each genotype and compared to the BAX- and BAK-
of transformed cells beyond the initial site of emergence, limiting expressing controls.
or preventing invasion of surrounding tissues. Tumor growth
Antibodies and Western blottingitself may restrict essential growth factors, thereby promoting
The following antibodies were used for Western blotting analysis: the rabbitapoptosis. Cell survival in the absence of normal cell-cell attach-
polyclonal antibody (NT) against amino acids 1–21 of human BAX, and the
ment may also enhance the tumorigenic potential of transformed rabbit polyclonal antibody (NT) raised against amino acids 23–37 of human
epithelial cells. Finally, the resistance of BAX- and BAK-deficient BAK (Upstate Biotechnology, Lake Placid, NY); the mouse monoclonal anti-
transformed BMK cell lines to apoptosis mediated by death bodies directed against p53 (pAB421); the anti-adenovirus 2 E1A (M73);
and actin (Oncogene Research Products, Boston, MA). Cell extracts werereceptor signaling pathways may enhance their tumorigenic po-
analyzed by SDS-PAGE and semidry blotted as previously described (Pereztential. Indeed, TRAIL-deficient mice are tumor prone (Cretney
and White, 2000). Proteins were detected by antibody as indicated andet al., 2002). If apoptosis mediated by BAX and BAK were responsi-
visualized by enhanced chemiluminescence according to the manufacturer’s
ble for these types of activities, this could account for the dramatic specifications (Amersham Pharmacia Biotechnology, Buckingshire, En-
enhancement of tumorigenesis of mouse xenographs observed gland).
here, and may be a property of human tumorigenesis. Designing
bax and bak genotyping of tumor-derived cell linesspecific strategies to overcome survival in the absence of BAX
DNA was purified from cell lines using DNeasy tissue kit according to theand BAK function may provide novel opportunities in anticancer
manufacturer’s specifications (Qiagen, Valencia, CA). bax genotyping wasdrug discovery. Furthermore, understanding the events regulat-
preformed by PCR as previously described (Shindler et al., 1997) using
ing a p53-independent apoptotic pathway that functions in tu- Advantage cDNA PCR according to the manufacturer’s specifications (Clon-
mor suppression may reveal novel targets for effective combina- tech Laboraories Inc., Palo Alto, CA). bak genotyping was preformed by
PCR as previously described (Lindsten et al., 2000) using Advantage-GCtorial therapeutic approaches to cancer treatment.
Genomic PCR according to the manufacturer’s specifications (Clontech La-
boraories Inc., Palo Alto, CA).Experimental procedures
Staurosporine-mediated apoptosis assayCell culture
BMK cell lines were untreated or treated with staurosporine (4M) (Sigma, St.E1A- and p53DD-transformed BMK cell lines were derived from wild-type
Louis, MO). After 24 hr of treatment, cells were harvested by trypsinization,mice and mice deficient for p53, BAX, BAK, or BAX and BAK (Degenhardt
centrifuged, and resuspended in PBS. Cells were diluted 1:100 in 0.25%et al., 2002). W1, W2, W3, X1, X2, X3, K1, K2, K3, D1, D2, and D3 were
trypan blue solution (Gibco BRL, Grand Island, NY) and counted in a hemocy-generated from three litters of mice obtained from three matings: mice were
tometer to assess number of dead blue cells from the total number of cellsbred by crossing bax/ bak/ with bax/ bak/; bax/ bak/ with bax/
counted.bak/; and bax/ bak/ with bax/ bak/. Independent cell lines for each
genotype were derived from at least two separate mice, except for the cell
Acknowledgmentslines deficient for both BAX and BAK, which were derived from a single
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The authors thank White lab members for helpful discussions, Dr. Arnoldp53/-1, and p53/-2 were generated from littermates of a single mating:
Rabson (Center for Advanced Biotechnology and Medicine, University ofp53/ with p53/. Tumor-derived cell lines were generated by simply me-
Medicine and Dentistry, New Jersey) for assistance with tumor pathology,chanically disrupting tumor tissue that was grown in culture under the same
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